These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26471360)

  • 1. Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer.
    Moughon DL; He H; Schokrpur S; Jiang ZK; Yaqoob M; David J; Lin C; Iruela-Arispe ML; Dorigo O; Wu L
    Cancer Res; 2015 Nov; 75(22):4742-52. PubMed ID: 26471360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
    Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
    PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.
    Conway JG; McDonald B; Parham J; Keith B; Rusnak DW; Shaw E; Jansen M; Lin P; Payne A; Crosby RM; Johnson JH; Frick L; Lin MH; Depee S; Tadepalli S; Votta B; James I; Fuller K; Chambers TJ; Kull FC; Chamberlain SD; Hutchins JT
    Proc Natl Acad Sci U S A; 2005 Nov; 102(44):16078-83. PubMed ID: 16249345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic and Cardiac Depletion of M2 Macrophage through CSF-1R Signaling Inhibition Alters Cardiac Function Post Myocardial Infarction.
    Leblond AL; Klinkert K; Martin K; Turner EC; Kumar AH; Browne T; Caplice NM
    PLoS One; 2015; 10(9):e0137515. PubMed ID: 26407006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.
    Chalmers SA; Wen J; Shum J; Doerner J; Herlitz L; Putterman C
    Clin Immunol; 2017 Dec; 185():100-108. PubMed ID: 27570219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
    Wilson AJ; Saskowski J; Barham W; Khabele D; Yull F
    Mol Cancer; 2015 Nov; 14():192. PubMed ID: 26552746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment With the CSF1R Antagonist GW2580, Sensitizes Microglia to Reactive Oxygen Species.
    Soto-Diaz K; Vailati-Riboni M; Louie AY; McKim DB; Gaskins HR; Johnson RW; Steelman AJ
    Front Immunol; 2021; 12():734349. PubMed ID: 34899694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage depletion ameliorates nephritis induced by pathogenic antibodies.
    Chalmers SA; Chitu V; Herlitz LC; Sahu R; Stanley ER; Putterman C
    J Autoimmun; 2015 Feb; 57():42-52. PubMed ID: 25554644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic Consequences of Malignant Ascites in Epithelial Ovarian Cancer Surgery*: A Prospective Substudy of a Randomized Controlled Trial.
    Hunsicker O; Fotopoulou C; Pietzner K; Koch M; Krannich A; Sehouli J; Spies C; Feldheiser A
    Medicine (Baltimore); 2015 Dec; 94(49):e2108. PubMed ID: 26656336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
    Colombo N; Mangili G; Mammoliti S; Kalling M; Tholander B; Sternas L; Buzenet G; Chamberlain D
    Gynecol Oncol; 2012 Apr; 125(1):42-7. PubMed ID: 22112608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.
    Zhao H; Li X; Chen D; Cai J; Fu Y; Kang H; Gao J; Gao K; Du N
    Med Oncol; 2015 Feb; 32(2):292. PubMed ID: 25609006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression].
    Cai YJ; Zheng DY; Luo RC; Chen JZ; Li AM; Xi JL; Ding XM
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):647-9. PubMed ID: 17545079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression.
    Prat M; Coulson K; Blot C; Jacquemin G; Romano M; Renoud ML; AlaEddine M; Le Naour A; Authier H; Rahabi MC; Benmoussa K; Salon M; Parny M; Delord JP; Ferron G; Lefèvre L; Couderc B; Coste A
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo.
    Yukita A; Asano M; Okamoto T; Mizutani S; Suzuki H
    Anticancer Res; 2000; 20(1A):155-60. PubMed ID: 10769648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells.
    Liu L; Wang X; Li X; Wu X; Tang M; Wang X
    Oncol Rep; 2018 Feb; 39(2):818-826. PubMed ID: 29251331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
    Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
    Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.
    Szender JB; Emmons T; Belliotti S; Dickson D; Khan A; Morrell K; Khan ANMN; Singel KL; Mayor PC; Moysich KB; Odunsi K; Segal BH; Eng KH
    Gynecol Oncol; 2017 Sep; 146(3):491-497. PubMed ID: 28624153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
    Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
    Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
    Glass EB; Hoover AA; Bullock KK; Madden MZ; Reinfeld BI; Harris W; Parker D; Hufnagel DH; Crispens MA; Khabele D; Rathmell WK; Rathmell JC; Wilson AJ; Giorgio TD; Yull FE
    BMC Cancer; 2022 May; 22(1):497. PubMed ID: 35513776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.
    Rafehi S; Ramos Valdes Y; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
    Endocr Relat Cancer; 2016 Mar; 23(3):147-59. PubMed ID: 26647384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.